New drug combo for advanced cervical cancer shows early promise but study halted
NCT ID NCT04651127
First seen Mar 27, 2026 · Last updated Apr 25, 2026 · Updated 4 times
Summary
This study tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread, returned, or could not be removed by surgery. The goal was to see if the combination was safe and could shrink tumors. Only 5 women took part before the study was stopped early. The results are limited, but the approach aims to boost the immune system's ability to fight cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Centre
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.